CMS Announces Plans to Cover Alzheimer’s Treatment Drug and the PET/CT Scans Needed to Begin treating Patients With This Drug
September 1, 2023
New England PET is fully prepared to perform these crucial Beta Amyloid PET/CT Scans at all five of our locations!
On July 6, 2023 CMS announced that it would cover the Alzheimer’s Treatment drug Lequembi and, as part of this decision, required the treating physician to submit proof of a positive Beta Amyloid PET/CT scan prior to starting any treatment.
Then, on July 20, 2023 CMS published a Proposed Decision Memo indicating that it would cover the Beta Amyloid PET/CT scan required before starting treatment with any FDA approved Alzheimer’s Treatment drug.
New England PET is fully prepared to perform these crucial Beta Amyloid PET/CT Scans at all five of our locations!
